Cipla (CIPLA) Q1 24/25 earnings summary

Executive summary

• Branded prescription business grew 10% YoY, with chronic therapies now 61.5% of the mix; North America achieved record quarterly revenue of $250 million, up 13% YoY, and South Africa prescription business maintained its number one position.

• Q1FY25 revenue reached INR 6,694 crore, up 7% YoY, with EBITDA at INR 1,716 crore, up 14% YoY, and PAT at INR 1,178 crore, up 17% YoY.

• Operating profitability improved, with EBITDA margin at 25.6% and PAT margin at 17.6% of revenue.

• Transition to a new distribution model in India trade generics completed, improving channel efficiency.

• Unaudited standalone and consolidated financial results for the quarter ended 30 June 2024 were approved and released.

Financial highlights

• Quarterly revenue reached INR 6,694 crore, up 7% YoY, led by India, North America, and South Africa.

• EBITDA margin (excluding other income) at 25.6%, up 154 bps YoY; EBITDA grew 14% YoY.

• Profit after tax was INR 1,178 crore, 17.6% of sales; effective tax rate at 27%.

• R&D expenses at INR 353 crore, 5.3% of revenue, with guidance of 5-6% of sales for the year.

• Net cash position remains strong with cash equivalents near INR 9,000 crore and debt at INR 547 crore.

Outlook and guidance

• Focus on growing ahead of the market in India branded prescriptions and swift recovery in trade generics.

• North America to prioritize commercial execution and peptide portfolio launches, with sustainable quarterly run rate expected at $235-240 million.

• EBITDA margin guidance maintained at 24.5%-25.5% for the year; ROIC above 30%.

• R&D spend expected at 5-6% of sales; CapEx to rise to INR 1,500-1,800 crore, mostly in India and focused on growth.

• Chronic therapies and branded prescription portfolio expected to drive long-term growth in India.